BOSTON SCIENTIFIC CORP

CEO Michael Mahoney’s massive $0 sale of 386K Boston Scientific shares raises questions about exec confidence and hints at short‑term volatility, yet the firm’s robust pipeline still offers upside.

Boston Scientific’s insider buying of deferred stock units signals board confidence in a rebound—insider buys, product wins, and a bullish outlook for investors.

Explore how Boston Scientific’s senior exec Emily Woodworth’s recent trades signal potential rebound amid regulatory wins and earnings buzz.

Boston Scientific insider buying surge shows CEO confidence – 95k shares bought at $24‑27, hinting growth in neurovascular and peripheral devices.